We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Titan Pharmaceuticals Inc | NASDAQ:TTNP | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.08 | 1.19% | 6.82 | 6.56 | 6.92 | 6.82 | 6.58 | 6.69 | 1,686 | 21:00:16 |
Reverse Split Ratio
|
| |
Approximate Number of New Shares
Following the Reverse Split |
| |||
1-for-15
|
| | | | 13,117,546 | | |
1-for-20
|
| | | | 9,838,159 | | |
1-for-25
|
| | | | 7,870,528 | | |
1-for-30
|
| | | | 6,558,773 | | |
Reverse Split Ratio
|
| |
Approximate Number of Underlying Shares
Following the Reverse Split |
| |||
1-for-15
|
| | | | 7,121,970 | | |
1-for-20
|
| | | | 5,341,477 | | |
1-for-25
|
| | | | 4,273,182 | | |
1-for-30
|
| | | | 3,560,985 | | |
Name and Address of Beneficial Owner(1)
|
| |
Shares Beneficially
Owned(2) |
| |
Percent of Shares
Beneficially Owned |
| ||||||
Joseph A. Akers(3)
|
| | | | 74,974 | | | | | | *% | | |
Sunil Bhonsle(4)
|
| | | | 309,155 | | | | | | * | | |
Kate Devarney, Ph.D.(5)
|
| | | | 55,876 | | | | | | * | | |
M. David MacFarlane, Ph.D.(6)
|
| | | | 39,327 | | | | | | * | | |
James R. McNab, Jr.(7)
|
| | | | 89,475 | | | | | | * | | |
Marc Rubin, M.D.(8)
|
| | | | 329,250 | | | | | | * | | |
Scott A. Smith(9)
|
| | | | 2,501 | | | | | | * | | |
All executive officers and directors as a group (7) persons
|
| | | | 900,558 | | | | | | *% | | |
☐ FOR
|
☐ AGAINST
|
☐ ABSTAIN |
| | | | Titan Pharmaceuticals, Inc. | | |||
| | | | By: | | |
/s/ Kate Devarney, Ph.D.
Kate Devarney, PhD., President and Chief Operating Officer
|
|
1 Year Titan Pharmaceuticals Chart |
1 Month Titan Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions